Prior Authorization for Ustekinumab Dose Escalation Negatively Affects Outcomes in Patients With Inflammatory Bowel Disease

被引：1
|
作者：
Choi, David K. [1 ]
Puangampai, Archariya [1 ]
Rubin, David T. [1 ]
机构：
[1] Univ Chicago, Med Inflammatory Bowel Dis Ctr, Chicago, IL 60637 USA
来源：
ANNALS OF PHARMACOTHERAPY | 2022年 / 56卷 / 11期
关键词：
CROHNS-DISEASE; EXPERIENCE;
D O I：
10.1177/10600280221080986
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：1279 / 1280
页数：2
相关论文
共 50 条
  • [1] PREDICTORS AND OUTCOMES OF USTEKINUMAB DOSE ESCALATION IN INFLAMMATORY BOWEL DISEASE
    Petrov, Jessica C.
    Fine, Sean
    Al Bawardy, Badr
    [J]. GASTROENTEROLOGY, 2022, 162 (07) : S824 - S824
  • [2] Prior Anti-TNF-Alpha Exposure Is Associated with Ustekinumab Dose Escalation in Patients With Inflammatory Bowel Disease
    Tran, Nancy
    Lavergne, Alexa
    Scherl, Ellen
    Longman, Randy
    Lukin, Dana
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S907 - S908
  • [3] COSTS OF DOSE ESCALATION AMONG PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH VEDOLIZUMAB AND USTEKINUMAB IN PORTUGAL
    Lopes da Cruz, J. P.
    Faria, M.
    Aleixo, A. S.
    Pereira, F.
    [J]. VALUE IN HEALTH, 2023, 26 (12) : S504 - S505
  • [4] De-escalation of biological therapy in inflammatory bowel disease patients following prior dose escalation
    Thomas, Pepijn W. A.
    Smits, Lisa J. T.
    Te Groen, Maarten
    West, Rachel L.
    Russel, Maurice G. V. M.
    Jansen, Jeroen M.
    Romkens, Tessa E. H.
    Hoentjen, Frank
    [J]. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2022, 34 (05) : 488 - 495
  • [5] OUTCOMES OF DOSE ESCALATION WITH ADALIMUMAB (ADA) IN INFLAMMATORY BOWEL DISEASE
    Dillon, A.
    Rowan, C.
    Gibson, D.
    Keegan, D.
    Byrne, K.
    Mulcahy, H.
    Cullen, G.
    Doherty, G.
    [J]. GUT, 2013, 62
  • [6] PREDICTORS AND OUTCOMES OF VEDOLIZUMAB DOSE ESCALATION IN INFLAMMATORY BOWEL DISEASE
    Levine, Louis
    Gaidos, Jill K.
    Proctor, Deborah D.
    Al Bawardy, Badr
    [J]. GASTROENTEROLOGY, 2021, 160 (06) : S703 - S703
  • [7] Off-label dose escalation of Ustekinumab in Inflammatory Bowel Disease patients. Incidence rate, timing, dosing patterns and outcomes
    Garcia-Morales, N.
    Carmona, A.
    Ayude, M.
    Gayoso-Rey, M.
    Agra-Blanco, I.
    Parga, M. L. De Castro
    Rodriguez-Prada, I.
    [J]. JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1662 - I1662
  • [8] Delays Related to Prior Authorization in Inflammatory Bowel Disease
    Constant, Brad D.
    de Zoeten, Edwin F.
    Stahl, Marisa G.
    Vajravelu, Ravy K.
    Lewis, James D.
    Fennimore, Blair
    Gerich, Mark E.
    Scott, Frank, I
    [J]. PEDIATRICS, 2022, 149 (03)
  • [9] Prior Authorization of Biologics in the Management of Inflammatory Bowel Disease
    Loeb, Lauren
    Nasir, Ayan
    Picco, Michael F.
    Hashash, Jana G.
    Kinnucan, Jami A.
    Farraye, Francis A.
    [J]. INFLAMMATORY BOWEL DISEASES, 2023,
  • [10] Clinical Outcomes of Ustekinumab in Inflammatory Bowel Disease
    Gara, Sirisha K.
    Guntipalli, Prathima
    Marzban, Sima
    Taqi, Muhammad
    Aryal, Vinayak
    Khan, Qurat ul ain
    Shah, Shahtaj A.
    Akbariromani, Hanieh
    Salinger, Darren
    Diaz-Miret, Miguel
    [J]. CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (10)
12345